Acambis won a $425 million, 10-year contract with the CDC to provide warm-base manufacturing capability for the ACAM2000 smallpox vaccine. If the CDC purchases more doses of the vaccine than the minimum, Acambis could make up $660 million.
Acambis will establish a U.S.-based manufacturing capability for the vaccine, deliver against CDC orders for a minimum of 9 million doses per annum for the last eight years of the contract, and undertake activities to maintain its product licence. The CDC may purchase up to 39 million doses in the last six contract years if necessary, which would increase the value of the contract to some $660 million.
Acambis will transfer the entire ACAM2000 production process to its facilities in Canton, MA, and Rockville, MD.
ACAM 2000 was developed under a contract with the CDC, and over 195 million doses of the vaccine have been delivered to the CDC for the strategic national stockpile.